Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 10 Carcinoma, Non-Small-Cell Lung 6 Prostatic Neoplasms 4 Lymphoma, Large B-Cell, Diffuse 4 Leukemia, Myeloid, Acute 4 Triple Negative Breast Neoplasms 3 Stomach Neoplasms 3 Recurrence 3 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Multiple Myeloma 3 Lung Neoplasms 3 Thrombosis 2 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Neoplasms 2 Nasopharyngeal Carcinoma 2 Esophageal Squamous Cell Carcinoma 2 Disease 2 Carcinoma, Transitional Cell 2 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thyroid Cancer, Papillary 1 Thrombophilia 1 Thrombocytopenia 1 Thoracic Neoplasms 1 Skin Neoplasms 1 Pituitary Neoplasms 1 Pediatric Solid Tumor, Unspecified, Protocol Specific 1

Interventions

folfirinox 1 devimistat 1 Paclitaxel 1 Oxaliplatin 1 Leucovorin 1 Irinotecan 1 Injections 1 Gemcitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Pancreatic Cancer Metastatic × Injections × Clear all

NCT06752811 2026-02-10

pompom

Shanghai Yizhong Pharmaceutical Co., Ltd.

Phase 3 Recruiting

Gastrointestinal

Pancreatic Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡